{
    "xml": "<topic id=\"PHP4691\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/denosumab\" basename=\"denosumab\" title=\"DENOSUMAB\">\n<title>DENOSUMAB</title>\n<body>\n<data name=\"vtmid\">446457007</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_805434570\" title=\"Monoclonal antibodies\">Monoclonal antibodies</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n</body>\n<topic id=\"PHP64202\" outputclass=\"drugAction\" rev=\"1.9\" parent=\"/drugs/denosumab\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>\n<b>Denosumab</b> is a human monoclonal antibody that inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64215\" outputclass=\"importantSafetyInformation\" rev=\"1.32\" parent=\"/drugs/denosumab\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">MHRA/CHM advice: Denosumab: atypical femoral fractures (February 2013)</p>\n<p>Atypical femoral fractures have been reported rarely in patients receiving denosumab for the long-term treatment (2.5 or more years) of postmenopausal osteoporosis.</p>\n<p>Patients should be advised to report any new or unusual thigh, hip, or groin pain during treatment with denosumab.</p>\n<p>Discontinuation of denosumab in patients suspected to have an atypical femoral fracture should be considered after an assessment of the benefits and risks of continued treatment.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">MHRA/CHM advice: Denosumab: minimising the risk of osteonecrosis of the jaw; monitoring for hypocalcaemia&#8212;updated recommendations (September 2014) and Denosumab: osteonecrosis of the jaw&#8212;further measures to minimise risk (July 2015)</p>\n<p>Denosumab is associated with a risk of osteonecrosis of the jaw (ONJ) and with a risk of hypocalcaemia.</p>\n<p>\n<b>Osteonecrosis of the jaw</b>\n</p>\n<p>Osteonecrosis of the jaw is a well-known and common side-effect in patients receiving denosumab 120&#8239;mg for cancer. Risk factors include smoking, old age, poor oral hygiene, invasive dental procedures (including tooth extractions, dental implants, oral surgery), comorbidity (including dental disease, anaemia, coagulopathy, infection), advanced cancer, previous treatment with bisphosphonates, and concomitant treatments (including chemotherapy, anti-angiogenic biologics, corticosteroids, and radiotherapy to head and neck). The following precautions are now recommended to reduce the risk of ONJ:</p>\n<p>Denosumab 120&#8239;mg (cancer indication)</p>\n<ul>\n<li>A dental examination and appropriate preventative dentistry before starting treatment are now recommended for all patients</li>\n<li>Do not start denosumab in patients with a dental or jaw condition requiring surgery, or in patients who have unhealed lesions from dental or oral surgery</li>\n</ul>\n<p>Denosumab 60&#8239;mg (osteoporosis indication)</p>\n<ul>\n<li>Check for ONJ risk factors before starting treatment. A dental examination and appropriate preventative dentistry are now recommended for patients with risk factors</li>\n</ul>\n<p>All patients should be given a patient reminder card and informed of the risk of ONJ. Advise patients to tell their doctor if they have any problems with their mouth or teeth before starting treatment, if they wear dentures they should make sure their dentures fit properly before starting treatment, to maintain good oral hygiene, receive routine dental check-ups during treatment, and immediately report any oral symptoms such as dental mobility, pain, swelling, non-healing sores or discharge to a doctor and dentist. Patients should tell their doctor and dentist that they are receiving denosumab if they need dental treatment or dental surgery.</p>\n<p>\n<b>Hypocalcaemia</b>\n</p>\n<p>Denosumab is associated with a risk of hypocalcaemia. This risk increases with the degree of renal impairment. Hypocalcaemia usually occurs in the first weeks of denosumab treatment, but it can also occur later in treatment.</p>\n<p>Plasma-calcium concentration monitoring is recommended for denosumab 120&#8239;mg (cancer indication):</p>\n<ul>\n<li>before the first dose</li>\n<li>within two weeks after the initial dose</li>\n<li>if suspected symptoms of hypocalcaemia occur</li>\n<li>consider monitoring more frequently in patients with risk factors for hypocalcaemia (e.g. severe renal impairment, creatinine clearance less than 30&#8239;mL/minute)</li>\n</ul>\n<p>Plasma-calcium concentration monitoring is recommended for denosumab 60&#8239;mg (osteoporosis indication):</p>\n<ul>\n<li>before each dose</li>\n<li>within two weeks after the initial dose in patients with risk factors for hypocalcaemia (e.g. severe renal impairment, creatinine clearance less than 30&#8239;mL/minute)</li>\n<li>if suspected symptoms of hypocalcaemia occur</li>\n</ul>\n<p>All patients should be advised to report symptoms of hypocalcaemia to their doctor (e.g. muscle spasms, twitches, cramps, numbness or tingling in the fingers, toes, or around the mouth).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64219\" outputclass=\"contraindications\" rev=\"1.24\" parent=\"/drugs/denosumab\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Hypocalcaemia</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64251\" outputclass=\"cautions\" rev=\"1.15\" parent=\"/drugs/denosumab\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Atypical femoral fractures</ph>; <ph outputclass=\"caution\">hypocalcaemia</ph>; <ph outputclass=\"caution\">osteonecrosis of the jaw&#8212;consider temporary interruption of treatment if occurs</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64035\" outputclass=\"sideEffects\" rev=\"1.22\" parent=\"/drugs/denosumab\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Abdominal discomfort</ph>; <ph outputclass=\"sideEffect\">cataracts</ph>; <ph outputclass=\"sideEffect\">constipation</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">dyspnoea</ph>; <ph outputclass=\"sideEffect\">eczema</ph>; <ph outputclass=\"sideEffect\">hypocalcaemia (fatal cases reported)</ph>; <ph outputclass=\"sideEffect\">hypophosphataemia</ph>; <ph outputclass=\"sideEffect\">musculoskeletal pain</ph>; <ph outputclass=\"sideEffect\">osteonecrosis of the jaw</ph>; <ph outputclass=\"sideEffect\">pain in extremity</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">sciatica</ph>; <ph outputclass=\"sideEffect\">sweating</ph>; <ph outputclass=\"sideEffect\">upper respiratory tract infection</ph>; <ph outputclass=\"sideEffect\">urinary tract infection</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Cellulitis (seek prompt medical attention)</ph>; <ph outputclass=\"sideEffect\">diverticulitis</ph>; <ph outputclass=\"sideEffect\">ear infection</ph>; <ph outputclass=\"sideEffect\">skin infections (seek prompt medical attention)</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Atypical femoral fractures</ph>; <ph outputclass=\"sideEffect\">osteonecrosis of the jaw</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64230\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/denosumab\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Ensure effective contraception in women of child-bearing potential, during treatment and for at least 5 months after stopping treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64132\" outputclass=\"pregnancy\" parent=\"/drugs/denosumab\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid&#8212;toxicity in <i>animal</i> studies; risk of toxicity increases with each trimester&#8212;advise women who become pregnant during treatment to enrol in the manufacturer's Pregnancy Surveillance Programme (consult product literature).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64263\" outputclass=\"breastFeeding\" parent=\"/drugs/denosumab\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid (if women do decide to breast-feed during treatment, they should enrol in the manufacturer's Lactation Surveillance Programme&#8212;consult product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64090\" outputclass=\"renalImpairment\" parent=\"/drugs/denosumab\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Increased risk of hypocalcaemia if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63944\" outputclass=\"monitoringRequirements\" parent=\"/drugs/denosumab\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Correct hypocalcaemia and vitamin D deficiency before starting. Monitor plasma-calcium concentration during therapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64114\" outputclass=\"patientAndCarerAdvice\" rev=\"1.26\" parent=\"/drugs/denosumab\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"patientResources\">\n<sectiondiv>\n<p>A patient reminder card should be provided (risk of osteonecrosis of the jaw).</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p outputclass=\"title\">Atypical femoral fractures</p>\n<p>Patients should be advised to report any new or unusual thigh, hip, or groin pain during treatment with denosumab.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Osteonecrosis of the jaw</p>\n<p>All patients should be informed to maintain good oral hygiene, receive routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain, or swelling to a doctor and dentist.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Hypocalaemia</p>\n<p>All patients should be advised to report symptoms of hypocalcaemia to their doctor (e.g. muscle spasms, twitches, cramps, numbness or tingling in the fingers, toes, or around the mouth).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63883\" outputclass=\"nationalFunding\" rev=\"1.37\" parent=\"/drugs/denosumab\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA204</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Denosumab for the prevention of osteoporotic fractures in postmenopausal women (October 2010)</p>\r\n<p>Denosumab is recommended as a treatment option for the <i>primary prevention</i> of osteoporotic fragility fractures in postmenopausal women at increased risk of fractures:</p>\r\n<ul>\r\n<li>who are unable to comply with the special instructions for administering alendronate and risedronate, or have an intolerance of, or a contra-indication to, those treatments <b>and</b>\r\n</li>\r\n<li>who comply with particular combinations of bone mineral density measurement, age, and independent risk factors for fracture, as indicated in the full NICE guidance.</li>\r\n</ul>\r\n<p>Denosumab is recommended as a treatment option for the <i>secondary prevention</i> of osteoporotic fragility fractures only in postmenopausal women at increased risk of fractures who are unable to comply with the special instructions for administering alendronate and risedronate, or have an intolerance of, or a contra-indication to, those treatments.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA204\">www.nice.org.uk/TA204</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA265</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (October 2012)</p>\r\n<p>Denosumab is recommended for the prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate if:</p>\r\n<ul>\r\n<li>bisphosphonates would otherwise be prescribed, <b>and</b>\r\n</li>\r\n<li>the manufacturer provides denosumab with the discount agreed in the patient access scheme.</li>\r\n</ul>\r\n<p>Denosumab is <b>not</b> recommended for preventing skeletal-related events in adults with bone metastases from prostate cancer.</p>\r\n<p>Patients with bone metastases from solid tumours currently receiving denosumab whose disease does not meet the above criteria can continue treatment until they and their clinician consider it appropriate to stop.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA265\">www.nice.org.uk/TA265</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP4691-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/denosumab\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74884\" title=\"Solution for injection\" namespace=\"/drugs/denosumab/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74884\" namespace=\"/drugs/denosumab/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP4691",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/denosumab",
    "basename": "denosumab",
    "title": "DENOSUMAB",
    "vtmid": "446457007",
    "drugClassification": [
        "Monoclonal antibodies"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Denosumab is a human monoclonal antibody that inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption.",
                "html": "<p>\n<b>Denosumab</b> is a human monoclonal antibody that inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption.</p>"
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "title": "MHRA/CHM advice: Denosumab: atypical femoral fractures (February 2013)",
                "textContent": "Atypical femoral fractures have been reported rarely in patients receiving denosumab for the long-term treatment (2.5 or more years) of postmenopausal osteoporosis.\n\nPatients should be advised to report any new or unusual thigh, hip, or groin pain during treatment with denosumab.\n\nDiscontinuation of denosumab in patients suspected to have an atypical femoral fracture should be considered after an assessment of the benefits and risks of continued treatment.",
                "html": "<p>Atypical femoral fractures have been reported rarely in patients receiving denosumab for the long-term treatment (2.5 or more years) of postmenopausal osteoporosis.</p><p>Patients should be advised to report any new or unusual thigh, hip, or groin pain during treatment with denosumab.</p><p>Discontinuation of denosumab in patients suspected to have an atypical femoral fracture should be considered after an assessment of the benefits and risks of continued treatment.</p>"
            },
            {
                "type": "importantSafetyInformation",
                "title": "MHRA/CHM advice: Denosumab: minimising the risk of osteonecrosis of the jaw; monitoring for hypocalcaemia&#8212;updated recommendations (September 2014) and Denosumab: osteonecrosis of the jaw&#8212;further measures to minimise risk (July 2015)",
                "textContent": "Denosumab is associated with a risk of osteonecrosis of the jaw (ONJ) and with a risk of hypocalcaemia.\n\nOsteonecrosis of the jaw\n\nOsteonecrosis of the jaw is a well-known and common side-effect in patients receiving denosumab 120 mg for cancer. Risk factors include smoking, old age, poor oral hygiene, invasive dental procedures (including tooth extractions, dental implants, oral surgery), comorbidity (including dental disease, anaemia, coagulopathy, infection), advanced cancer, previous treatment with bisphosphonates, and concomitant treatments (including chemotherapy, anti-angiogenic biologics, corticosteroids, and radiotherapy to head and neck). The following precautions are now recommended to reduce the risk of ONJ:\n\nDenosumab 120 mg (cancer indication)\n\nA dental examination and appropriate preventative dentistry before starting treatment are now recommended for all patients Do not start denosumab in patients with a dental or jaw condition requiring surgery, or in patients who have unhealed lesions from dental or oral surgery\n\nDenosumab 60 mg (osteoporosis indication)\n\nCheck for ONJ risk factors before starting treatment. A dental examination and appropriate preventative dentistry are now recommended for patients with risk factors\n\nAll patients should be given a patient reminder card and informed of the risk of ONJ. Advise patients to tell their doctor if they have any problems with their mouth or teeth before starting treatment, if they wear dentures they should make sure their dentures fit properly before starting treatment, to maintain good oral hygiene, receive routine dental check-ups during treatment, and immediately report any oral symptoms such as dental mobility, pain, swelling, non-healing sores or discharge to a doctor and dentist. Patients should tell their doctor and dentist that they are receiving denosumab if they need dental treatment or dental surgery.\n\nHypocalcaemia\n\nDenosumab is associated with a risk of hypocalcaemia. This risk increases with the degree of renal impairment. Hypocalcaemia usually occurs in the first weeks of denosumab treatment, but it can also occur later in treatment.\n\nPlasma-calcium concentration monitoring is recommended for denosumab 120 mg (cancer indication):\n\nbefore the first dose within two weeks after the initial dose if suspected symptoms of hypocalcaemia occur consider monitoring more frequently in patients with risk factors for hypocalcaemia (e.g. severe renal impairment, creatinine clearance less than 30 mL/minute)\n\nPlasma-calcium concentration monitoring is recommended for denosumab 60 mg (osteoporosis indication):\n\nbefore each dose within two weeks after the initial dose in patients with risk factors for hypocalcaemia (e.g. severe renal impairment, creatinine clearance less than 30 mL/minute) if suspected symptoms of hypocalcaemia occur\n\nAll patients should be advised to report symptoms of hypocalcaemia to their doctor (e.g. muscle spasms, twitches, cramps, numbness or tingling in the fingers, toes, or around the mouth).",
                "html": "<p>Denosumab is associated with a risk of osteonecrosis of the jaw (ONJ) and with a risk of hypocalcaemia.</p><p>\n<b>Osteonecrosis of the jaw</b>\n</p><p>Osteonecrosis of the jaw is a well-known and common side-effect in patients receiving denosumab 120&#8239;mg for cancer. Risk factors include smoking, old age, poor oral hygiene, invasive dental procedures (including tooth extractions, dental implants, oral surgery), comorbidity (including dental disease, anaemia, coagulopathy, infection), advanced cancer, previous treatment with bisphosphonates, and concomitant treatments (including chemotherapy, anti-angiogenic biologics, corticosteroids, and radiotherapy to head and neck). The following precautions are now recommended to reduce the risk of ONJ:</p><p>Denosumab 120&#8239;mg (cancer indication)</p><ul>\n<li>A dental examination and appropriate preventative dentistry before starting treatment are now recommended for all patients</li>\n<li>Do not start denosumab in patients with a dental or jaw condition requiring surgery, or in patients who have unhealed lesions from dental or oral surgery</li>\n</ul><p>Denosumab 60&#8239;mg (osteoporosis indication)</p><ul>\n<li>Check for ONJ risk factors before starting treatment. A dental examination and appropriate preventative dentistry are now recommended for patients with risk factors</li>\n</ul><p>All patients should be given a patient reminder card and informed of the risk of ONJ. Advise patients to tell their doctor if they have any problems with their mouth or teeth before starting treatment, if they wear dentures they should make sure their dentures fit properly before starting treatment, to maintain good oral hygiene, receive routine dental check-ups during treatment, and immediately report any oral symptoms such as dental mobility, pain, swelling, non-healing sores or discharge to a doctor and dentist. Patients should tell their doctor and dentist that they are receiving denosumab if they need dental treatment or dental surgery.</p><p>\n<b>Hypocalcaemia</b>\n</p><p>Denosumab is associated with a risk of hypocalcaemia. This risk increases with the degree of renal impairment. Hypocalcaemia usually occurs in the first weeks of denosumab treatment, but it can also occur later in treatment.</p><p>Plasma-calcium concentration monitoring is recommended for denosumab 120&#8239;mg (cancer indication):</p><ul>\n<li>before the first dose</li>\n<li>within two weeks after the initial dose</li>\n<li>if suspected symptoms of hypocalcaemia occur</li>\n<li>consider monitoring more frequently in patients with risk factors for hypocalcaemia (e.g. severe renal impairment, creatinine clearance less than 30&#8239;mL/minute)</li>\n</ul><p>Plasma-calcium concentration monitoring is recommended for denosumab 60&#8239;mg (osteoporosis indication):</p><ul>\n<li>before each dose</li>\n<li>within two weeks after the initial dose in patients with risk factors for hypocalcaemia (e.g. severe renal impairment, creatinine clearance less than 30&#8239;mL/minute)</li>\n<li>if suspected symptoms of hypocalcaemia occur</li>\n</ul><p>All patients should be advised to report symptoms of hypocalcaemia to their doctor (e.g. muscle spasms, twitches, cramps, numbness or tingling in the fingers, toes, or around the mouth).</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Hypocalcaemia",
                "html": "Hypocalcaemia"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Atypical femoral fractures",
                "html": "Atypical femoral fractures"
            },
            {
                "type": "cautions",
                "textContent": "hypocalcaemia",
                "html": "hypocalcaemia"
            },
            {
                "type": "cautions",
                "textContent": "osteonecrosis of the jaw&#8212;consider temporary interruption of treatment if occurs",
                "html": "osteonecrosis of the jaw&#8212;consider temporary interruption of treatment if occurs"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Abdominal discomfort",
                        "html": "Abdominal discomfort",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "cataracts",
                        "html": "cataracts",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "constipation",
                        "html": "constipation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dyspnoea",
                        "html": "dyspnoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "eczema",
                        "html": "eczema",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypocalcaemia (fatal cases reported)",
                        "html": "hypocalcaemia (fatal cases reported)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypophosphataemia",
                        "html": "hypophosphataemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "musculoskeletal pain",
                        "html": "musculoskeletal pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "osteonecrosis of the jaw",
                        "html": "osteonecrosis of the jaw",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "pain in extremity",
                        "html": "pain in extremity",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "sciatica",
                        "html": "sciatica",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "sweating",
                        "html": "sweating",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "upper respiratory tract infection",
                        "html": "upper respiratory tract infection",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "urinary tract infection",
                        "html": "urinary tract infection",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Cellulitis (seek prompt medical attention)",
                        "html": "Cellulitis (seek prompt medical attention)",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "diverticulitis",
                        "html": "diverticulitis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "ear infection",
                        "html": "ear infection",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "skin infections (seek prompt medical attention)",
                        "html": "skin infections (seek prompt medical attention)",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Atypical femoral fractures",
                        "html": "Atypical femoral fractures",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "osteonecrosis of the jaw",
                        "html": "osteonecrosis of the jaw",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ]
            }
        }
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Ensure effective contraception in women of child-bearing potential, during treatment and for at least 5 months after stopping treatment.",
                "html": "<p>Ensure effective contraception in women of child-bearing potential, during treatment and for at least 5 months after stopping treatment.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid&#8212;toxicity in animal studies; risk of toxicity increases with each trimester&#8212;advise women who become pregnant during treatment to enrol in the manufacturer's Pregnancy Surveillance Programme (consult product literature).",
                "html": "<p>Avoid&#8212;toxicity in <i>animal</i> studies; risk of toxicity increases with each trimester&#8212;advise women who become pregnant during treatment to enrol in the manufacturer's Pregnancy Surveillance Programme (consult product literature).</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid (if women do decide to breast-feed during treatment, they should enrol in the manufacturer's Lactation Surveillance Programme&#8212;consult product literature.",
                "html": "<p>Avoid (if women do decide to breast-feed during treatment, they should enrol in the manufacturer's Lactation Surveillance Programme&#8212;consult product literature.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Increased risk of hypocalcaemia if eGFR less than 30 mL/minute/1.73 m2.",
                "html": "<p>Increased risk of hypocalcaemia if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Correct hypocalcaemia and vitamin D deficiency before starting. Monitor plasma-calcium concentration during therapy.",
                "html": "<p>Correct hypocalcaemia and vitamin D deficiency before starting. Monitor plasma-calcium concentration during therapy.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "patientResources": [
            {
                "type": "patientResources",
                "textContent": "A patient reminder card should be provided (risk of osteonecrosis of the jaw).",
                "html": "<p>A patient reminder card should be provided (risk of osteonecrosis of the jaw).</p>"
            }
        ],
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "title": "Atypical femoral fractures",
                "textContent": "Patients should be advised to report any new or unusual thigh, hip, or groin pain during treatment with denosumab.",
                "html": "<p>Patients should be advised to report any new or unusual thigh, hip, or groin pain during treatment with denosumab.</p>"
            },
            {
                "type": "generalPatientAdvice",
                "title": "Osteonecrosis of the jaw",
                "textContent": "All patients should be informed to maintain good oral hygiene, receive routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain, or swelling to a doctor and dentist.",
                "html": "<p>All patients should be informed to maintain good oral hygiene, receive routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain, or swelling to a doctor and dentist.</p>"
            },
            {
                "type": "generalPatientAdvice",
                "title": "Hypocalaemia",
                "textContent": "All patients should be advised to report symptoms of hypocalcaemia to their doctor (e.g. muscle spasms, twitches, cramps, numbness or tingling in the fingers, toes, or around the mouth).",
                "html": "<p>All patients should be advised to report symptoms of hypocalcaemia to their doctor (e.g. muscle spasms, twitches, cramps, numbness or tingling in the fingers, toes, or around the mouth).</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA204",
                        "label": "www.nice.org.uk/TA204"
                    }
                ],
                "fundingIdentifier": "NICE TA204",
                "textContent": "Denosumab for the prevention of osteoporotic fractures in postmenopausal women (October 2010) Denosumab is recommended as a treatment option for the primary prevention of osteoporotic fragility fractures in postmenopausal women at increased risk of fractures: who are unable to comply with the special instructions for administering alendronate and risedronate, or have an intolerance of, or a contra-indication to, those treatments and who comply with particular combinations of bone mineral density measurement, age, and independent risk factors for fracture, as indicated in the full NICE guidance. Denosumab is recommended as a treatment option for the secondary prevention of osteoporotic fragility fractures only in postmenopausal women at increased risk of fractures who are unable to comply with the special instructions for administering alendronate and risedronate, or have an intolerance of, or a contra-indication to, those treatments.\n\nwww.nice.org.uk/TA204",
                "html": "<p outputclass=\"title\">Denosumab for the prevention of osteoporotic fractures in postmenopausal women (October 2010)</p> <p>Denosumab is recommended as a treatment option for the <i>primary prevention</i> of osteoporotic fragility fractures in postmenopausal women at increased risk of fractures:</p> <ul> <li>who are unable to comply with the special instructions for administering alendronate and risedronate, or have an intolerance of, or a contra-indication to, those treatments <b>and</b> </li> <li>who comply with particular combinations of bone mineral density measurement, age, and independent risk factors for fracture, as indicated in the full NICE guidance.</li> </ul> <p>Denosumab is recommended as a treatment option for the <i>secondary prevention</i> of osteoporotic fragility fractures only in postmenopausal women at increased risk of fractures who are unable to comply with the special instructions for administering alendronate and risedronate, or have an intolerance of, or a contra-indication to, those treatments.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA204\">www.nice.org.uk/TA204</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA265",
                        "label": "www.nice.org.uk/TA265"
                    }
                ],
                "fundingIdentifier": "NICE TA265",
                "textContent": "Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (October 2012) Denosumab is recommended for the prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate if: bisphosphonates would otherwise be prescribed, and the manufacturer provides denosumab with the discount agreed in the patient access scheme. Denosumab is not recommended for preventing skeletal-related events in adults with bone metastases from prostate cancer. Patients with bone metastases from solid tumours currently receiving denosumab whose disease does not meet the above criteria can continue treatment until they and their clinician consider it appropriate to stop.\n\nwww.nice.org.uk/TA265",
                "html": "<p outputclass=\"title\">Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (October 2012)</p> <p>Denosumab is recommended for the prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate if:</p> <ul> <li>bisphosphonates would otherwise be prescribed, <b>and</b> </li> <li>the manufacturer provides denosumab with the discount agreed in the patient access scheme.</li> </ul> <p>Denosumab is <b>not</b> recommended for preventing skeletal-related events in adults with bone metastases from prostate cancer.</p> <p>Patients with bone metastases from solid tumours currently receiving denosumab whose disease does not meet the above criteria can continue treatment until they and their clinician consider it appropriate to stop.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA265\">www.nice.org.uk/TA265</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP74884",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP74884",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}